Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12325546 | 0.85 | MAPT (0.49) | ALDH1A1LMNASLC6A9SLC6A5MAPT | |
| SCHEMBL1172592 | 0.82 | SIRT6 (0.55) | ALDH1A1LMNAMAPTKCNJ1KCNH2 | |
| SCHEMBL1172676 | 0.81 | SLC6A9 (0.54) | ALDH1A1LMNASLC6A9SLC6A5MAPT | |
| SCHEMBL5131832 | 0.81 | SLC6A9 (0.48) | ALDH1A1LMNASLC6A9SLC6A5MAPT | |
| SCHEMBL22032842 | 0.79 | ALDH1A1 (0.48) | ALDH1A1KDM4ELMNAMAPTMEN1 | |
| SCHEMBL14032706 | 0.79 | GPR119 (0.42) | LMNAGPR119RORC | |
| SCHEMBL5132626 | 0.79 | KCNJ1 (0.49) | ALDH1A1KDM4ESLC6A9SLC6A5MAPT | |
| SCHEMBL4428990 | 0.77 | MAPT (0.48) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4500240 | 0.75 | GPR119 (0.58) | GPR119RORC | |
| SCHEMBL12325543 | 0.74 | KCNJ1 (0.36) | ALDH1A1LMNASLC6A9SLC6A5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | ALDH1A1 1143/4885KDM4E 1632/4885LMNA 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.